#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Stroke is a major cause of dementia , especially in the elderly .
3-1	17-23	Stroke	abstract	new	coref	3-3[4_0]
3-2	24-26	is	_	_	_	_
3-3	27-28	a	abstract[4]	giv[4]	coref	21-17[135_4]
3-4	29-34	major	abstract[4]	giv[4]	_	_
3-5	35-40	cause	abstract[4]	giv[4]	_	_
3-6	41-43	of	abstract[4]	giv[4]	_	_
3-7	44-52	dementia	abstract[4]|abstract	giv[4]|new	coref	4-3[6_0]
3-8	53-54	,	abstract[4]	giv[4]	_	_
3-9	55-65	especially	abstract[4]	giv[4]	_	_
3-10	66-68	in	abstract[4]	giv[4]	_	_
3-11	69-72	the	abstract[4]	giv[4]	_	_
3-12	73-80	elderly	abstract[4]	giv[4]	_	_
3-13	81-82	.	_	_	_	_

#Text=Specifically , the one-year post-stroke dementia ( PSD ) rates after first-ever and recurrent stroke are approximately 10 % and 30 % , respectively .
4-1	83-95	Specifically	_	_	_	_
4-2	96-97	,	_	_	_	_
4-3	98-101	the	abstract[6]	giv[6]	coref	5-4[13_6]
4-4	102-110	one-year	abstract[6]	giv[6]	_	_
4-5	111-122	post-stroke	abstract[6]	giv[6]	_	_
4-6	123-131	dementia	abstract[6]	giv[6]	_	_
4-7	132-133	(	_	_	_	_
4-8	134-137	PSD	abstract	new	_	_
4-9	138-139	)	_	_	_	_
4-10	140-145	rates	_	_	_	_
4-11	146-151	after	_	_	_	_
4-12	152-162	first-ever	event[8]	new[8]	coref	11-31[0_8]
4-13	163-166	and	event[8]	new[8]	_	_
4-14	167-176	recurrent	event[8]	new[8]	_	_
4-15	177-183	stroke	event[8]	new[8]	_	_
4-16	184-187	are	_	_	_	_
4-17	188-201	approximately	quantity[9]	new[9]	_	_
4-18	202-204	10	quantity[9]	new[9]	_	_
4-19	205-206	%	quantity[9]	new[9]	_	_
4-20	207-210	and	_	_	_	_
4-21	211-213	30	quantity[10]	new[10]	_	_
4-22	214-215	%	quantity[10]	new[10]	_	_
4-23	216-217	,	_	_	_	_
4-24	218-230	respectively	_	_	_	_
4-25	231-232	.	_	_	_	_

#Text=Neuropathological studies into Alzheimer ’s disease ( AD ) have shown that AD pathology is often concomitant with ischemic lesions in the elderly .
5-1	233-250	Neuropathological	event[11]	new[11]	coref	24-31[159_11]
5-2	251-258	studies	event[11]	new[11]	_	_
5-3	259-263	into	event[11]	new[11]	_	_
5-4	264-273	Alzheimer	event[11]|person[12]|abstract[13]	new[11]|new[12]|giv[13]	appos|appos	5-8[0_13]|5-8[0_13]
5-5	274-276	’s	event[11]|person[12]|abstract[13]	new[11]|new[12]|giv[13]	_	_
5-6	277-284	disease	event[11]|abstract[13]	new[11]|giv[13]	_	_
5-7	285-286	(	_	_	_	_
5-8	287-289	AD	abstract	giv	coref	5-13
5-9	290-291	)	_	_	_	_
5-10	292-296	have	_	_	_	_
5-11	297-302	shown	_	_	_	_
5-12	303-307	that	_	_	_	_
5-13	308-310	AD	abstract|abstract[16]	giv|new[16]	coref|coref|coref|coref	6-35|7-11[35_16]|6-35|7-11[35_16]
5-14	311-320	pathology	abstract[16]	new[16]	_	_
5-15	321-323	is	_	_	_	_
5-16	324-329	often	_	_	_	_
5-17	330-341	concomitant	_	_	_	_
5-18	342-346	with	_	_	_	_
5-19	347-355	ischemic	object|abstract[18]	new|new[18]	coref|coref	19-30[117_0]|19-30[117_0]
5-20	356-363	lesions	abstract[18]	new[18]	_	_
5-21	364-366	in	_	_	_	_
5-22	367-370	the	_	_	_	_
5-23	371-378	elderly	_	_	_	_
5-24	379-380	.	_	_	_	_

#Text=For instance , evidence from the Nun Study showed that lacunes increase the risk of clinical expression of cognitive impairment more than 20 times during early Braak stages that were yet sufficient to produce dementia symptoms .
6-1	381-384	For	_	_	_	_
6-2	385-393	instance	_	_	_	_
6-3	394-395	,	_	_	_	_
6-4	396-404	evidence	abstract[19]	new[19]	_	_
6-5	405-409	from	abstract[19]	new[19]	_	_
6-6	410-413	the	abstract[19]|abstract[21]	new[19]|new[21]	coref	19-1[107_21]
6-7	414-417	Nun	abstract[19]|person|abstract[21]	new[19]|new|new[21]	_	_
6-8	418-423	Study	abstract[19]|abstract[21]	new[19]|new[21]	_	_
6-9	424-430	showed	_	_	_	_
6-10	431-435	that	_	_	_	_
6-11	436-443	lacunes	abstract	new	_	_
6-12	444-452	increase	_	_	_	_
6-13	453-456	the	abstract[23]	new[23]	coref	22-9[140_23]
6-14	457-461	risk	abstract[23]	new[23]	_	_
6-15	462-464	of	abstract[23]	new[23]	_	_
6-16	465-473	clinical	abstract[23]|abstract[24]	new[23]|new[24]	_	_
6-17	474-484	expression	abstract[23]|abstract[24]	new[23]|new[24]	_	_
6-18	485-487	of	abstract[23]|abstract[24]	new[23]|new[24]	_	_
6-19	488-497	cognitive	abstract[23]|abstract[24]|abstract[25]	new[23]|new[24]|new[25]	ana	7-1[0_25]
6-20	498-508	impairment	abstract[23]|abstract[24]|abstract[25]	new[23]|new[24]|new[25]	_	_
6-21	509-513	more	abstract[23]|abstract[24]|abstract[25]|time[26]	new[23]|new[24]|new[25]|new[26]	_	_
6-22	514-518	than	abstract[23]|abstract[24]|abstract[25]|time[26]	new[23]|new[24]|new[25]|new[26]	_	_
6-23	519-521	20	abstract[23]|abstract[24]|abstract[25]|time[26]	new[23]|new[24]|new[25]|new[26]	_	_
6-24	522-527	times	abstract[23]|abstract[24]|abstract[25]|time[26]	new[23]|new[24]|new[25]|new[26]	_	_
6-25	528-534	during	_	_	_	_
6-26	535-540	early	abstract[28]	new[28]	_	_
6-27	541-546	Braak	abstract|abstract[28]	new|new[28]	_	_
6-28	547-553	stages	abstract[28]	new[28]	_	_
6-29	554-558	that	_	_	_	_
6-30	559-563	were	_	_	_	_
6-31	564-567	yet	_	_	_	_
6-32	568-578	sufficient	_	_	_	_
6-33	579-581	to	_	_	_	_
6-34	582-589	produce	_	_	_	_
6-35	590-598	dementia	abstract|abstract[30]	giv|new[30]	coref|coref	7-11|7-11
6-36	599-607	symptoms	abstract[30]	new[30]	_	_
6-37	608-609	.	_	_	_	_

#Text=It follows that vascular insults enhance the clinical expression of AD pathology .
7-1	610-612	It	abstract	giv	coref	14-11[82_0]
7-2	613-620	follows	_	_	_	_
7-3	621-625	that	_	_	_	_
7-4	626-634	vascular	abstract[32]	new[32]	_	_
7-5	635-642	insults	abstract[32]	new[32]	_	_
7-6	643-650	enhance	_	_	_	_
7-7	651-654	the	abstract[33]	new[33]	_	_
7-8	655-663	clinical	abstract[33]	new[33]	_	_
7-9	664-674	expression	abstract[33]	new[33]	_	_
7-10	675-677	of	abstract[33]	new[33]	_	_
7-11	678-680	AD	abstract[33]|abstract|abstract[35]	new[33]|giv|giv[35]	coref|coref	8-1[36_0]|8-1[36_0]
7-12	681-690	pathology	abstract[33]|abstract[35]	new[33]|giv[35]	_	_
7-13	691-692	.	_	_	_	_

#Text=Vascular dementia is more prevalent in men and in populations affected by cerebral small-vessel disease , including Asians , Hispanics , and Africans .
8-1	693-701	Vascular	abstract[36]	giv[36]	coref	8-13[39_36]
8-2	702-710	dementia	abstract[36]	giv[36]	_	_
8-3	711-713	is	_	_	_	_
8-4	714-718	more	_	_	_	_
8-5	719-728	prevalent	_	_	_	_
8-6	729-731	in	_	_	_	_
8-7	732-735	men	person	new	_	_
8-8	736-739	and	_	_	_	_
8-9	740-742	in	_	_	_	_
8-10	743-754	populations	person	new	_	_
8-11	755-763	affected	_	_	_	_
8-12	764-766	by	_	_	_	_
8-13	767-775	cerebral	abstract[39]	giv[39]	coref	16-12[0_39]
8-14	776-788	small-vessel	abstract[39]	giv[39]	_	_
8-15	789-796	disease	abstract[39]	giv[39]	_	_
8-16	797-798	,	abstract[39]	giv[39]	_	_
8-17	799-808	including	abstract[39]	giv[39]	_	_
8-18	809-815	Asians	abstract[39]|person	giv[39]|new	_	_
8-19	816-817	,	abstract[39]	giv[39]	_	_
8-20	818-827	Hispanics	abstract[39]|person	giv[39]|new	_	_
8-21	828-829	,	abstract[39]	giv[39]	_	_
8-22	830-833	and	abstract[39]	giv[39]	_	_
8-23	834-842	Africans	abstract[39]|place	giv[39]|new	_	_
8-24	843-844	.	_	_	_	_

#Text=The cholinergic system is distributed throughout the central nervous system , playing a role in neurotransmission and possibly mediating various neuroprotective functions .
9-1	845-848	The	abstract[43]	new[43]	_	_
9-2	849-860	cholinergic	abstract[43]	new[43]	_	_
9-3	861-867	system	abstract[43]	new[43]	_	_
9-4	868-870	is	_	_	_	_
9-5	871-882	distributed	_	_	_	_
9-6	883-893	throughout	_	_	_	_
9-7	894-897	the	place[44]	new[44]	_	_
9-8	898-905	central	place[44]	new[44]	_	_
9-9	906-913	nervous	place[44]	new[44]	_	_
9-10	914-920	system	place[44]	new[44]	_	_
9-11	921-922	,	_	_	_	_
9-12	923-930	playing	_	_	_	_
9-13	931-932	a	abstract[45]	new[45]	coref	16-3[86_45]
9-14	933-937	role	abstract[45]	new[45]	_	_
9-15	938-940	in	abstract[45]	new[45]	_	_
9-16	941-958	neurotransmission	abstract[45]|abstract	new[45]|new	coref	10-3[48_0]
9-17	959-962	and	_	_	_	_
9-18	963-971	possibly	_	_	_	_
9-19	972-981	mediating	_	_	_	_
9-20	982-989	various	abstract[47]	new[47]	_	_
9-21	990-1005	neuroprotective	abstract[47]	new[47]	_	_
9-22	1006-1015	functions	abstract[47]	new[47]	_	_
9-23	1016-1017	.	_	_	_	_

#Text=Furthermore , cholinergic neurotransmission regulates the immune response during inflammation , in a pathway that involves nicotinic acetylcholine receptors ( nAChRs ) and inhibits peripheral cytokine release .
10-1	1018-1029	Furthermore	_	_	_	_
10-2	1030-1031	,	_	_	_	_
10-3	1032-1043	cholinergic	abstract[48]	giv[48]	_	_
10-4	1044-1061	neurotransmission	abstract[48]	giv[48]	_	_
10-5	1062-1071	regulates	_	_	_	_
10-6	1072-1075	the	abstract[49]	new[49]	_	_
10-7	1076-1082	immune	abstract[49]	new[49]	_	_
10-8	1083-1091	response	abstract[49]	new[49]	_	_
10-9	1092-1098	during	abstract[49]	new[49]	_	_
10-10	1099-1111	inflammation	abstract[49]|abstract[50]	new[49]|new[50]	coref	12-4[0_50]
10-11	1112-1113	,	abstract[49]|abstract[50]	new[49]|new[50]	_	_
10-12	1114-1116	in	abstract[49]|abstract[50]	new[49]|new[50]	_	_
10-13	1117-1118	a	abstract[49]|abstract[50]|abstract[51]	new[49]|new[50]|new[51]	_	_
10-14	1119-1126	pathway	abstract[49]|abstract[50]|abstract[51]	new[49]|new[50]|new[51]	_	_
10-15	1127-1131	that	_	_	_	_
10-16	1132-1140	involves	_	_	_	_
10-17	1141-1150	nicotinic	substance[53]	new[53]	coref	11-19[62_53]
10-18	1151-1164	acetylcholine	abstract|substance[53]	new|new[53]	coref	11-10
10-19	1165-1174	receptors	substance[53]	new[53]	_	_
10-20	1175-1176	(	_	_	_	_
10-21	1177-1183	nAChRs	place	new	_	_
10-22	1184-1185	)	_	_	_	_
10-23	1186-1189	and	_	_	_	_
10-24	1190-1198	inhibits	_	_	_	_
10-25	1199-1209	peripheral	event[56]	new[56]	coref	11-25[63_56]
10-26	1210-1218	cytokine	abstract|event[56]	new|new[56]	_	_
10-27	1219-1226	release	event[56]	new[56]	_	_
10-28	1227-1228	.	_	_	_	_

#Text=In particular , the efferent vagus nerve may release acetylcholine ( Ach ) , which subsequently binds with macrophage receptors and therefore may inhibit the release of inflammatory factors after stroke .
11-1	1229-1231	In	_	_	_	_
11-2	1232-1242	particular	_	_	_	_
11-3	1243-1244	,	_	_	_	_
11-4	1245-1248	the	object[58]	new[58]	_	_
11-5	1249-1257	efferent	object[58]	new[58]	_	_
11-6	1258-1263	vagus	object|object[58]	new|new[58]	_	_
11-7	1264-1269	nerve	object[58]	new[58]	_	_
11-8	1270-1273	may	_	_	_	_
11-9	1274-1281	release	_	_	_	_
11-10	1282-1295	acetylcholine	abstract	giv	appos	11-12
11-11	1296-1297	(	_	_	_	_
11-12	1298-1301	Ach	abstract	giv	coref	18-3
11-13	1302-1303	)	_	_	_	_
11-14	1304-1305	,	_	_	_	_
11-15	1306-1311	which	_	_	_	_
11-16	1312-1324	subsequently	_	_	_	_
11-17	1325-1330	binds	_	_	_	_
11-18	1331-1335	with	_	_	_	_
11-19	1336-1346	macrophage	place|substance[62]	new|giv[62]	_	_
11-20	1347-1356	receptors	substance[62]	giv[62]	_	_
11-21	1357-1360	and	_	_	_	_
11-22	1361-1370	therefore	_	_	_	_
11-23	1371-1374	may	_	_	_	_
11-24	1375-1382	inhibit	_	_	_	_
11-25	1383-1386	the	event[63]	giv[63]	_	_
11-26	1387-1394	release	event[63]	giv[63]	_	_
11-27	1395-1397	of	event[63]	giv[63]	_	_
11-28	1398-1410	inflammatory	event[63]|abstract[64]	giv[63]|new[64]	_	_
11-29	1411-1418	factors	event[63]|abstract[64]	giv[63]|new[64]	_	_
11-30	1419-1424	after	event[63]|abstract[64]	giv[63]|new[64]	_	_
11-31	1425-1431	stroke	event[63]|abstract[64]|event	giv[63]|new[64]|giv	coref	16-10
11-32	1432-1433	.	_	_	_	_

#Text=In addition to inflammation , excitotoxicity and energy failure following cerebral ischemia may also initiate intracellular death pathways and oxidative stress ( OS ) .
12-1	1434-1436	In	_	_	_	_
12-2	1437-1445	addition	_	_	_	_
12-3	1446-1448	to	_	_	_	_
12-4	1449-1461	inflammation	abstract	giv	coref	24-26
12-5	1462-1463	,	_	_	_	_
12-6	1464-1478	excitotoxicity	event	new	_	_
12-7	1479-1482	and	_	_	_	_
12-8	1483-1489	energy	substance|abstract[69]	new|new[69]	_	_
12-9	1490-1497	failure	abstract[69]	new[69]	_	_
12-10	1498-1507	following	_	_	_	_
12-11	1508-1516	cerebral	abstract[70]	new[70]	_	_
12-12	1517-1525	ischemia	abstract[70]	new[70]	_	_
12-13	1526-1529	may	_	_	_	_
12-14	1530-1534	also	_	_	_	_
12-15	1535-1543	initiate	_	_	_	_
12-16	1544-1557	intracellular	abstract[72]	new[72]	_	_
12-17	1558-1563	death	event|abstract[72]	new|new[72]	_	_
12-18	1564-1572	pathways	abstract[72]	new[72]	_	_
12-19	1573-1576	and	_	_	_	_
12-20	1577-1586	oxidative	abstract|abstract[74]	new|new[74]	appos|appos	12-23[0_74]|12-23[0_74]
12-21	1587-1593	stress	abstract[74]	new[74]	_	_
12-22	1594-1595	(	_	_	_	_
12-23	1596-1598	OS	abstract	giv	coref	13-8
12-24	1599-1600	)	_	_	_	_
12-25	1601-1602	.	_	_	_	_

#Text=The structural and functional changes caused by OS led to cholinergic and other cellular damage .
13-1	1603-1606	The	abstract[76]	new[76]	coref	24-36[160_76]
13-2	1607-1617	structural	abstract[76]	new[76]	_	_
13-3	1618-1621	and	abstract[76]	new[76]	_	_
13-4	1622-1632	functional	abstract[76]	new[76]	_	_
13-5	1633-1640	changes	abstract[76]	new[76]	_	_
13-6	1641-1647	caused	_	_	_	_
13-7	1648-1650	by	_	_	_	_
13-8	1651-1653	OS	abstract	giv	coref	15-8
13-9	1654-1657	led	_	_	_	_
13-10	1658-1660	to	_	_	_	_
13-11	1661-1672	cholinergic	abstract[78]	new[78]	coref	23-11[148_78]
13-12	1673-1676	and	abstract[78]	new[78]	_	_
13-13	1677-1682	other	abstract[78]	new[78]	_	_
13-14	1683-1691	cellular	abstract[78]	new[78]	_	_
13-15	1692-1698	damage	abstract[78]	new[78]	_	_
13-16	1699-1700	.	_	_	_	_

#Text=Cholinergic deficit further caused brain atrophy and finally resulted in cognitive impairment .
14-1	1701-1712	Cholinergic	abstract[79]	new[79]	_	_
14-2	1713-1720	deficit	abstract[79]	new[79]	_	_
14-3	1721-1728	further	_	_	_	_
14-4	1729-1735	caused	_	_	_	_
14-5	1736-1741	brain	object|abstract[81]	new|new[81]	_	_
14-6	1742-1749	atrophy	abstract[81]	new[81]	_	_
14-7	1750-1753	and	_	_	_	_
14-8	1754-1761	finally	_	_	_	_
14-9	1762-1770	resulted	abstract	new	coref|none	21-4[131_0]|14-9[0_131]
14-10	1771-1773	in	_	_	_	_
14-11	1774-1783	cognitive	abstract[82]	giv[82]	coref	19-18[113_82]
14-12	1784-1794	impairment	abstract[82]	giv[82]	_	_
14-13	1795-1796	.	_	_	_	_

#Text=Anticholinergic agents have been shown to regulate OS and alleviate apoptosis .
15-1	1797-1812	Anticholinergic	abstract[83]	new[83]	_	_
15-2	1813-1819	agents	abstract[83]	new[83]	_	_
15-3	1820-1824	have	_	_	_	_
15-4	1825-1829	been	_	_	_	_
15-5	1830-1835	shown	_	_	_	_
15-6	1836-1838	to	_	_	_	_
15-7	1839-1847	regulate	_	_	_	_
15-8	1848-1850	OS	abstract	giv	coref	16-17
15-9	1851-1854	and	_	_	_	_
15-10	1855-1864	alleviate	_	_	_	_
15-11	1865-1874	apoptosis	abstract	new	_	_
15-12	1875-1876	.	_	_	_	_

#Text=Therefore , a key role in the pathogenesis of stroke and dementia may be attributed to OS .
16-1	1877-1886	Therefore	_	_	_	_
16-2	1887-1888	,	_	_	_	_
16-3	1889-1890	a	abstract[86]	giv[86]	_	_
16-4	1891-1894	key	abstract[86]	giv[86]	_	_
16-5	1895-1899	role	abstract[86]	giv[86]	_	_
16-6	1900-1902	in	abstract[86]	giv[86]	_	_
16-7	1903-1906	the	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
16-8	1907-1919	pathogenesis	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
16-9	1920-1922	of	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
16-10	1923-1929	stroke	abstract[86]|abstract[87]|event	giv[86]|new[87]|giv	coref	19-23
16-11	1930-1933	and	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
16-12	1934-1942	dementia	abstract[86]|abstract[87]|abstract	giv[86]|new[87]|giv	coref	17-6[92_0]
16-13	1943-1946	may	_	_	_	_
16-14	1947-1949	be	_	_	_	_
16-15	1950-1960	attributed	_	_	_	_
16-16	1961-1963	to	_	_	_	_
16-17	1964-1966	OS	abstract	giv	_	_
16-18	1967-1968	.	_	_	_	_

#Text=Cholinergic dysfunction is related to vascular dementia .
17-1	1969-1980	Cholinergic	abstract[91]	new[91]	coref	21-8[133_91]
17-2	1981-1992	dysfunction	abstract[91]	new[91]	_	_
17-3	1993-1995	is	_	_	_	_
17-4	1996-2003	related	_	_	_	_
17-5	2004-2006	to	_	_	_	_
17-6	2007-2015	vascular	abstract[92]	giv[92]	coref	18-18[98_92]
17-7	2016-2024	dementia	abstract[92]	giv[92]	_	_
17-8	2025-2026	.	_	_	_	_

#Text=Specifically , Ach levels in the cerebrospinal fluid are up to 49 % lower in patients with small-vessel vascular dementia than in control patients , suggesting that cholinergic agents or cholinesterase inhibitors , both of which increase the Ach level , could be used to treat such patients .
18-1	2027-2039	Specifically	_	_	_	_
18-2	2040-2041	,	_	_	_	_
18-3	2042-2045	Ach	abstract|abstract[94]	giv|new[94]	coref|coref|coref|coref	18-39|24-43[164_94]|18-39|24-43[164_94]
18-4	2046-2052	levels	abstract[94]	new[94]	_	_
18-5	2053-2055	in	abstract[94]	new[94]	_	_
18-6	2056-2059	the	abstract[94]|object[95]	new[94]|new[95]	_	_
18-7	2060-2073	cerebrospinal	abstract[94]|object[95]	new[94]|new[95]	_	_
18-8	2074-2079	fluid	abstract[94]|object[95]	new[94]|new[95]	_	_
18-9	2080-2083	are	_	_	_	_
18-10	2084-2086	up	_	_	_	_
18-11	2087-2089	to	_	_	_	_
18-12	2090-2092	49	quantity[96]	new[96]	_	_
18-13	2093-2094	%	quantity[96]	new[96]	_	_
18-14	2095-2100	lower	quantity[96]	new[96]	_	_
18-15	2101-2103	in	_	_	_	_
18-16	2104-2112	patients	person[97]	new[97]	_	_
18-17	2113-2117	with	person[97]	new[97]	_	_
18-18	2118-2130	small-vessel	person[97]|abstract[98]	new[97]|giv[98]	coref	22-12[0_98]
18-19	2131-2139	vascular	person[97]|abstract[98]	new[97]|giv[98]	_	_
18-20	2140-2148	dementia	person[97]|abstract[98]	new[97]|giv[98]	_	_
18-21	2149-2153	than	person[97]|abstract[98]	new[97]|giv[98]	_	_
18-22	2154-2156	in	person[97]|abstract[98]	new[97]|giv[98]	_	_
18-23	2157-2164	control	person[97]|abstract[98]|abstract|person[100]	new[97]|giv[98]|new|new[100]	coref|coref	18-47[106_100]|18-47[106_100]
18-24	2165-2173	patients	person[97]|abstract[98]|person[100]	new[97]|giv[98]|new[100]	_	_
18-25	2174-2175	,	_	_	_	_
18-26	2176-2186	suggesting	_	_	_	_
18-27	2187-2191	that	_	_	_	_
18-28	2192-2203	cholinergic	person[101]	new[101]	_	_
18-29	2204-2210	agents	person[101]	new[101]	_	_
18-30	2211-2213	or	_	_	_	_
18-31	2214-2228	cholinesterase	object|object[103]	new|new[103]	coref|coref|coref|coref	22-3[137_103]|24-38[162_0]|22-3[137_103]|24-38[162_0]
18-32	2229-2239	inhibitors	object[103]	new[103]	_	_
18-33	2240-2241	,	_	_	_	_
18-34	2242-2246	both	_	_	_	_
18-35	2247-2249	of	_	_	_	_
18-36	2250-2255	which	_	_	_	_
18-37	2256-2264	increase	_	_	_	_
18-38	2265-2268	the	quantity[105]	new[105]	_	_
18-39	2269-2272	Ach	abstract|quantity[105]	giv|new[105]	coref	23-5
18-40	2273-2278	level	quantity[105]	new[105]	_	_
18-41	2279-2280	,	_	_	_	_
18-42	2281-2286	could	_	_	_	_
18-43	2287-2289	be	_	_	_	_
18-44	2290-2294	used	_	_	_	_
18-45	2295-2297	to	_	_	_	_
18-46	2298-2303	treat	_	_	_	_
18-47	2304-2308	such	person[106]	giv[106]	coref	19-15[112_106]
18-48	2309-2317	patients	person[106]	giv[106]	_	_
18-49	2318-2319	.	_	_	_	_

#Text=One pilot study showed that acetylcholinesterase ( AChE ) inhibitor promoted functional recovery in elderly patients with cognitive impairment who had suffered stroke . In a rat model of chronic ischemic , AChE activity was slightly decreased in the frontal cortex , but muscarinic acetylcholine receptor M1 was gradually depleted in cerebral cortex , striatum and hippocampus that are involved in cognitive function .
19-1	2320-2323	One	abstract[107]	giv[107]	coref	25-14[172_107]
19-2	2324-2329	pilot	abstract[107]	giv[107]	_	_
19-3	2330-2335	study	abstract[107]	giv[107]	_	_
19-4	2336-2342	showed	_	_	_	_
19-5	2343-2347	that	abstract[108]	new[108]	appos	19-8[0_108]
19-6	2348-2368	acetylcholinesterase	abstract[108]	new[108]	_	_
19-7	2369-2370	(	_	_	_	_
19-8	2371-2375	AChE	abstract	giv	coref	19-33
19-9	2376-2377	)	_	_	_	_
19-10	2378-2387	inhibitor	abstract	new	_	_
19-11	2388-2396	promoted	_	_	_	_
19-12	2397-2407	functional	abstract[111]	new[111]	_	_
19-13	2408-2416	recovery	abstract[111]	new[111]	_	_
19-14	2417-2419	in	abstract[111]	new[111]	_	_
19-15	2420-2427	elderly	abstract[111]|person[112]	new[111]|giv[112]	coref	20-5[126_112]
19-16	2428-2436	patients	abstract[111]|person[112]	new[111]|giv[112]	_	_
19-17	2437-2441	with	abstract[111]|person[112]	new[111]|giv[112]	_	_
19-18	2442-2451	cognitive	abstract[111]|person[112]|abstract[113]	new[111]|giv[112]|giv[113]	_	_
19-19	2452-2462	impairment	abstract[111]|person[112]|abstract[113]	new[111]|giv[112]|giv[113]	_	_
19-20	2463-2466	who	_	_	_	_
19-21	2467-2470	had	_	_	_	_
19-22	2471-2479	suffered	_	_	_	_
19-23	2480-2486	stroke	event	giv	coref	20-5
19-24	2487-2488	.	_	_	_	_
19-25	2489-2491	In	_	_	_	_
19-26	2492-2493	a	abstract[116]	new[116]	_	_
19-27	2494-2497	rat	animal|abstract[116]	new|new[116]	_	_
19-28	2498-2503	model	abstract[116]	new[116]	_	_
19-29	2504-2506	of	abstract[116]	new[116]	_	_
19-30	2507-2514	chronic	abstract[116]|object[117]	new[116]|giv[117]	coref	25-32[0_117]
19-31	2515-2523	ischemic	abstract[116]|object[117]	new[116]|giv[117]	_	_
19-32	2524-2525	,	_	_	_	_
19-33	2526-2530	AChE	place|abstract[119]	giv|new[119]	coref|coref|coref|coref	20-9|20-8[128_119]|20-9|20-8[128_119]
19-34	2531-2539	activity	abstract[119]	new[119]	_	_
19-35	2540-2543	was	_	_	_	_
19-36	2544-2552	slightly	_	_	_	_
19-37	2553-2562	decreased	_	_	_	_
19-38	2563-2565	in	_	_	_	_
19-39	2566-2569	the	object[120]	new[120]	coref	19-52[122_120]
19-40	2570-2577	frontal	object[120]	new[120]	_	_
19-41	2578-2584	cortex	object[120]	new[120]	_	_
19-42	2585-2586	,	_	_	_	_
19-43	2587-2590	but	_	_	_	_
19-44	2591-2601	muscarinic	object[121]	new[121]	_	_
19-45	2602-2615	acetylcholine	object[121]	new[121]	_	_
19-46	2616-2624	receptor	object[121]	new[121]	_	_
19-47	2625-2627	M1	object[121]	new[121]	_	_
19-48	2628-2631	was	_	_	_	_
19-49	2632-2641	gradually	_	_	_	_
19-50	2642-2650	depleted	_	_	_	_
19-51	2651-2653	in	_	_	_	_
19-52	2654-2662	cerebral	object[122]	giv[122]	_	_
19-53	2663-2669	cortex	object[122]	giv[122]	_	_
19-54	2670-2671	,	_	_	_	_
19-55	2672-2680	striatum	_	_	_	_
19-56	2681-2684	and	_	_	_	_
19-57	2685-2696	hippocampus	object	new	_	_
19-58	2697-2701	that	_	_	_	_
19-59	2702-2705	are	_	_	_	_
19-60	2706-2714	involved	_	_	_	_
19-61	2715-2717	in	_	_	_	_
19-62	2718-2727	cognitive	abstract[124]	new[124]	coref	23-7[146_124]
19-63	2728-2736	function	abstract[124]	new[124]	_	_
19-64	2737-2738	.	_	_	_	_

#Text=In addition , in stroke patients , reduced AChE activity was correlated with lower survival rate .
20-1	2739-2741	In	_	_	_	_
20-2	2742-2750	addition	_	_	_	_
20-3	2751-2752	,	_	_	_	_
20-4	2753-2755	in	_	_	_	_
20-5	2756-2762	stroke	event|person[126]	giv|giv[126]	coref|coref|coref|coref	21-14|22-12[142_126]|21-14|22-12[142_126]
20-6	2763-2771	patients	person[126]	giv[126]	_	_
20-7	2772-2773	,	_	_	_	_
20-8	2774-2781	reduced	abstract[128]	giv[128]	coref	24-45[165_128]
20-9	2782-2786	AChE	abstract|abstract[128]	giv|giv[128]	coref	21-8
20-10	2787-2795	activity	abstract[128]	giv[128]	_	_
20-11	2796-2799	was	_	_	_	_
20-12	2800-2810	correlated	_	_	_	_
20-13	2811-2815	with	_	_	_	_
20-14	2816-2821	lower	abstract[130]	new[130]	_	_
20-15	2822-2830	survival	event|abstract[130]	new|new[130]	_	_
20-16	2831-2835	rate	abstract[130]	new[130]	_	_
20-17	2836-2837	.	_	_	_	_

#Text=Taken together , these results suggest that AChE dysfunction is a result of stroke rather than a cause for further neurodegeneration .
21-1	2838-2843	Taken	_	_	_	_
21-2	2844-2852	together	_	_	_	_
21-3	2853-2854	,	_	_	_	_
21-4	2855-2860	these	abstract[131]	new[131]	_	_
21-5	2861-2868	results	abstract[131]	new[131]	_	_
21-6	2869-2876	suggest	_	_	_	_
21-7	2877-2881	that	_	_	_	_
21-8	2882-2886	AChE	abstract|abstract[133]	giv|giv[133]	coref|coref	23-7|23-7
21-9	2887-2898	dysfunction	abstract[133]	giv[133]	_	_
21-10	2899-2901	is	_	_	_	_
21-11	2902-2903	a	_	_	_	_
21-12	2904-2910	result	_	_	_	_
21-13	2911-2913	of	_	_	_	_
21-14	2914-2920	stroke	event	giv	coref	22-9
21-15	2921-2927	rather	_	_	_	_
21-16	2928-2932	than	_	_	_	_
21-17	2933-2934	a	abstract[135]	giv[135]	_	_
21-18	2935-2940	cause	abstract[135]	giv[135]	_	_
21-19	2941-2944	for	abstract[135]	giv[135]	_	_
21-20	2945-2952	further	abstract[135]|abstract[136]	giv[135]|new[136]	_	_
21-21	2953-2970	neurodegeneration	abstract[135]|abstract[136]	giv[135]|new[136]	_	_
21-22	2971-2972	.	_	_	_	_

#Text=Moreover , AChE inhibitors exert no effect on stroke risk in dementia patients .
22-1	2973-2981	Moreover	_	_	_	_
22-2	2982-2983	,	_	_	_	_
22-3	2984-2988	AChE	object[137]	giv[137]	_	_
22-4	2989-2999	inhibitors	object[137]	giv[137]	_	_
22-5	3000-3005	exert	_	_	_	_
22-6	3006-3008	no	abstract[138]	new[138]	_	_
22-7	3009-3015	effect	abstract[138]	new[138]	_	_
22-8	3016-3018	on	abstract[138]	new[138]	_	_
22-9	3019-3025	stroke	abstract[138]|event|abstract[140]	new[138]|giv|giv[140]	coref|coref	25-31[178_0]|25-31[178_0]
22-10	3026-3030	risk	abstract[138]|abstract[140]	new[138]|giv[140]	_	_
22-11	3031-3033	in	abstract[138]|abstract[140]	new[138]|giv[140]	_	_
22-12	3034-3042	dementia	abstract[138]|abstract[140]|abstract|person[142]	new[138]|giv[140]|giv|giv[142]	coref|coref	24-47[166_142]|24-47[166_142]
22-13	3043-3051	patients	abstract[138]|abstract[140]|person[142]	new[138]|giv[140]|giv[142]	_	_
22-14	3052-3053	.	_	_	_	_

#Text=These observations suggest that Ach and AChE function may predict post-stroke neuronal damage .
23-1	3054-3059	These	abstract[143]	new[143]	_	_
23-2	3060-3072	observations	abstract[143]	new[143]	_	_
23-3	3073-3080	suggest	_	_	_	_
23-4	3081-3085	that	_	_	_	_
23-5	3086-3089	Ach	abstract	giv	coref	25-2[169_0]
23-6	3090-3093	and	_	_	_	_
23-7	3094-3098	AChE	organization|abstract[146]	giv|giv[146]	coref|coref	25-7|25-7
23-8	3099-3107	function	abstract[146]	giv[146]	_	_
23-9	3108-3111	may	_	_	_	_
23-10	3112-3119	predict	_	_	_	_
23-11	3120-3131	post-stroke	abstract[148]	giv[148]	_	_
23-12	3132-3140	neuronal	person|abstract[148]	new|giv[148]	_	_
23-13	3141-3147	damage	abstract[148]	giv[148]	_	_
23-14	3148-3149	.	_	_	_	_

#Text=To date , only a few blood biomarkers for predicting PSD have been examined ( e. g. , D-amino acid oxidase , β-secretase , and inflammation markers ) , and few studies have focused on changes in blood cholinesterase ( ChE ) levels and activity in patients with PSD .
24-1	3150-3152	To	_	_	_	_
24-2	3153-3157	date	time	new	_	_
24-3	3158-3159	,	_	_	_	_
24-4	3160-3164	only	abstract[151]	new[151]	_	_
24-5	3165-3166	a	abstract[151]	new[151]	_	_
24-6	3167-3170	few	abstract[151]	new[151]	_	_
24-7	3171-3176	blood	substance|abstract[151]	new|new[151]	coref	24-38
24-8	3177-3187	biomarkers	abstract[151]	new[151]	_	_
24-9	3188-3191	for	_	_	_	_
24-10	3192-3202	predicting	_	_	_	_
24-11	3203-3206	PSD	abstract	new	_	_
24-12	3207-3211	have	_	_	_	_
24-13	3212-3216	been	_	_	_	_
24-14	3217-3225	examined	_	_	_	_
24-15	3226-3227	(	_	_	_	_
24-16	3228-3230	e.	_	_	_	_
24-17	3231-3233	g.	_	_	_	_
24-18	3234-3235	,	_	_	_	_
24-19	3236-3243	D-amino	object	new	_	_
24-20	3244-3248	acid	substance|abstract[155]	new|new[155]	_	_
24-21	3249-3256	oxidase	abstract[155]	new[155]	_	_
24-22	3257-3258	,	_	_	_	_
24-23	3259-3270	β-secretase	substance	new	_	_
24-24	3271-3272	,	_	_	_	_
24-25	3273-3276	and	_	_	_	_
24-26	3277-3289	inflammation	abstract|abstract[158]	giv|new[158]	_	_
24-27	3290-3297	markers	abstract[158]	new[158]	_	_
24-28	3298-3299	)	_	_	_	_
24-29	3300-3301	,	_	_	_	_
24-30	3302-3305	and	_	_	_	_
24-31	3306-3309	few	event[159]	giv[159]	_	_
24-32	3310-3317	studies	event[159]	giv[159]	_	_
24-33	3318-3322	have	_	_	_	_
24-34	3323-3330	focused	_	_	_	_
24-35	3331-3333	on	_	_	_	_
24-36	3334-3341	changes	abstract[160]	giv[160]	_	_
24-37	3342-3344	in	abstract[160]	giv[160]	_	_
24-38	3345-3350	blood	abstract[160]|substance|abstract[162]	giv[160]|giv|giv[162]	appos|appos	24-41[0_162]|24-41[0_162]
24-39	3351-3365	cholinesterase	abstract[160]|abstract[162]	giv[160]|giv[162]	_	_
24-40	3366-3367	(	_	_	_	_
24-41	3368-3371	ChE	abstract	giv	_	_
24-42	3372-3373	)	_	_	_	_
24-43	3374-3380	levels	abstract[164]	giv[164]	_	_
24-44	3381-3384	and	abstract[164]	giv[164]	_	_
24-45	3385-3393	activity	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
24-46	3394-3396	in	abstract[164]|abstract[165]	giv[164]|giv[165]	_	_
24-47	3397-3405	patients	abstract[164]|abstract[165]|person[166]	giv[164]|giv[165]|giv[166]	coref	25-29[176_166]
24-48	3406-3410	with	abstract[164]|abstract[165]|person[166]	giv[164]|giv[165]|giv[166]	_	_
24-49	3411-3414	PSD	abstract[164]|abstract[165]|person[166]|abstract	giv[164]|giv[165]|giv[166]|new	_	_
24-50	3415-3416	.	_	_	_	_

#Text=Since plasma Ach is metabolized by AChE and butylcholinesterase ( BChE ) , the present study examined the functional activities of these two enzymes in a population of patients with chronic ischemic stroke ( IS ) .
25-1	3417-3422	Since	_	_	_	_
25-2	3423-3429	plasma	abstract|abstract[169]	new|giv[169]	_	_
25-3	3430-3433	Ach	abstract[169]	giv[169]	_	_
25-4	3434-3436	is	_	_	_	_
25-5	3437-3448	metabolized	_	_	_	_
25-6	3449-3451	by	_	_	_	_
25-7	3452-3456	AChE	substance	giv	_	_
25-8	3457-3460	and	_	_	_	_
25-9	3461-3480	butylcholinesterase	_	_	_	_
25-10	3481-3482	(	_	_	_	_
25-11	3483-3487	BChE	object	new	_	_
25-12	3488-3489	)	_	_	_	_
25-13	3490-3491	,	_	_	_	_
25-14	3492-3495	the	abstract[172]	giv[172]	_	_
25-15	3496-3503	present	abstract[172]	giv[172]	_	_
25-16	3504-3509	study	abstract[172]	giv[172]	_	_
25-17	3510-3518	examined	_	_	_	_
25-18	3519-3522	the	abstract[173]	new[173]	_	_
25-19	3523-3533	functional	abstract[173]	new[173]	_	_
25-20	3534-3544	activities	abstract[173]	new[173]	_	_
25-21	3545-3547	of	abstract[173]	new[173]	_	_
25-22	3548-3553	these	abstract[173]|substance[174]	new[173]|new[174]	_	_
25-23	3554-3557	two	abstract[173]|substance[174]	new[173]|new[174]	_	_
25-24	3558-3565	enzymes	abstract[173]|substance[174]	new[173]|new[174]	_	_
25-25	3566-3568	in	abstract[173]|substance[174]	new[173]|new[174]	_	_
25-26	3569-3570	a	abstract[173]|substance[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
25-27	3571-3581	population	abstract[173]|substance[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
25-28	3582-3584	of	abstract[173]|substance[174]|abstract[175]	new[173]|new[174]|new[175]	_	_
25-29	3585-3593	patients	abstract[173]|substance[174]|abstract[175]|person[176]	new[173]|new[174]|new[175]|giv[176]	_	_
25-30	3594-3598	with	abstract[173]|substance[174]|abstract[175]|person[176]	new[173]|new[174]|new[175]|giv[176]	_	_
25-31	3599-3606	chronic	abstract[173]|substance[174]|abstract[175]|person[176]|event[178]	new[173]|new[174]|new[175]|giv[176]|giv[178]	_	_
25-32	3607-3615	ischemic	abstract[173]|substance[174]|abstract[175]|person[176]|object|event[178]	new[173]|new[174]|new[175]|giv[176]|giv|giv[178]	_	_
25-33	3616-3622	stroke	abstract[173]|substance[174]|abstract[175]|person[176]|event[178]	new[173]|new[174]|new[175]|giv[176]|giv[178]	_	_
25-34	3623-3624	(	_	_	_	_
25-35	3625-3627	IS	abstract	new	_	_
25-36	3628-3629	)	_	_	_	_
25-37	3630-3631	.	_	_	_	_
